Preclinical
Researchers from UCLA believe they may have a possible new approach to treating, and potentially eradicating HIV.
The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences.
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
Exavir Therapeutics announced that it was able to eliminate HIV from human cells with lipid nanoparticle (LNP)-delivered Tat-targeted CRISPR-Cas9.
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
While it has yet to reach clinical trials, preclinical results with the company’s specially-tailored adeno-associated virus have been fortuitously auspicious.
The patch is not only painless, it requires less vaccine to generate the same or greater effects.
Unlike most companies addressing the diseases associated with aging, Rejuvenate Bio tackles multiple cardiac, metabolic and renal issues at once.
PRESS RELEASES